Table I.
Clinical characteristics of CLL patients.
| UPN | Gender (F/M) | Age (years) | Rai stage | Previous treatment | ZAP70 status | IgH mutation |
|---|---|---|---|---|---|---|
|
| ||||||
| I | F | 61 | 0 | None | Na | M |
| II | F | 74 | 3 | None | + | U |
| III | M | 73 | 1 | Chlorambucil | − | M |
| IV | M | 68 | 0 | None | − | M |
| V | M | 56 | 0 | None | − | M |
| VI | F | 74 | 3 | Chlorambucil | + | U |
| VII | F | 74 | 1 | Chlorambucil | + | U |
| VIII | F | 69 | 1 | Chlorambucil | − | Na |
| IX | F | 64 | 1 | Chlorambucil | − | M |
| X | M | 56 | 1 | None | + | U |
| XI | M | 73 | 4 | Chlorambucil | − | M |
| XII | F | 74 | 1 | Chlorambucil | + | U |
| XIII | M | 56 | 1 | None | + | U |
| XIV | F | 76 | 0 | None | − | M |
| XV | F | 75 | 1 | Chlorambucil | + | U |
| XVI | M | 59 | 3 | Chlorambucil/FCR | + | U |
| XVII | F | 63 | 0 | None | Na | M |
| XVIII | F | 68 | 1 | Dexamethasone | − | M |
FCR: Fludarabine, Cyclophosphamide and Rituximab; M: mutated; Na: not available; U: unmutated; UPN: unique patient number; ZAP70: zetaassociated protein of 70 kDa.